Company intelligence / Profile preview

ArrowBiome

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

ArrowBiome has demonstrated significant efficacy and selectivity with its lysin-based technology across multiple bacterial strains relevant to skin conditions such as acne and body odor. The approach allows for over 100 times lower doses of active ingredients compared to current products while maintaining a healthy microbiome balance and minimizing antibiotic resistance risk. Clinical validation and R&D are ongoing with initial focus on personal care applications.

Therapeutic areas: GastroenterologyDermatologyInfectious Diseases
Modalities: Engineered lysins (bacteriophage-derived proteins)
Industry: Biotech

Drug pipeline

1 asset

SmartArrow Plus

Preclinical

Partnerships

Singapore-MIT Alliance for Research and Technology (SMART)NTU Lee Kong Chian School of Medicine; seeking commercial partners in cosmeceuticals/personal care sectors

Beyond the preview

Go deeper on ArrowBiome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArrowBiome.